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Little literature exists on the safety of early pregnancy following chemotherapy. Here we assess the rate of relapse and foetal
outcome in women who have completed single and multi-agent chemotherapy for gestational trophoblastic tumours. The
records of 1532 patients treated for persistent gestational trophoblastic tumours at Charing Cross Hospital between 1969 and
1998 were reviewed. Patients were deﬁned as receiving single agent or multi-agent treatment. Relapse rates and foetal
outcome were reviewed in the 230 patients who became pregnant within 12 months of completing chemotherapy. In the
single agent group 153 (22%) of 691 patients conceived early. Three subsequently relapsed. In the multi-agent group, 77
(10%) of 779 patients conceived early, two then relapsed. Relapse rates were 2% (3 out of 153) and 2.5% (2 out of 77) for
each group compared to 5% and 5.6% in the comparative non-pregnant groups. Outcomes of 230 early pregnancies: 164
(71%) delivered at full term, 35 (15%) terminations, 26 (11%) spontaneous abortions, three (1.3%) new hydatidiform moles
and two (1%) stillbirths. Early pregnancies were more common in the single agent group (P50.001), but spontaneous
miscarriages and terminations were more likely to occur in the multi-agent group (P=0.04 and 0.03, respectively). Of the full-
term pregnancies, three (1.8%) babies were born with congenital abnormalities. Patients in either group who conceive within
12 months of completing chemotherapy are not at increased risk of relapse. Though, we still advise avoiding pregnancy within
12 months of completing chemotherapy, those that do conceive can be reassured of a likely favourable outcome.
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Cancers in young women including gestational trophoblastic
tumours (GTT) (Seckl and Newlands, 1997), lymphomas (Vose
et al, 1988), leukaemias (Rai et al, 1981) and ovarian germ cell
tumours (Williams, 1996) are frequently cured with chemotherapy.
Fertility is usually preserved following chemotherapy in these
women (Berkowitz et al, 1998; Woolas et al, 1998), but little is
known about the risk of disease relapse or damage to the foetus
in women who conceive soon after completing treatment (Rustin
et al, 1984). Many physicians advise their patients to avoid preg-
nancy during the ﬁrst year of follow-up. It is thought that this
allows ova which have been damaged by chemotherapy to either
repair or undergo degeneration, reducing the risk of foetal malfor-
mation and/or spontaneous abortion. The greatest risk of tumour
relapse is within the ﬁrst year of remission and early pregnancy
can compromise both the surveillance systems used to detect
relapse as well as the safe institution of subsequent therapies. In
addition, it is possible that the hormonal changes associated with
pregnancy could in some instances actually promote tumour
growth and early recurrence.
Patients with GTT provide a very good example of these difﬁ-
culties. Nearly all women with the disease are cured with either
single agent or combination drug chemotherapy (Newlands et al,
1986). Fertility is usually preserved and the affected women
frequently wish to become pregnant again as soon as possible. This
is often because they were keen to start or continue their family
when they developed their original tumour. However, they are
routinely advised to avoid pregnancy for at least 1 year post
chemotherapy because: (1) most relapses occur in the ﬁrst year
post-treatment and these relapses are detected by a rising hCG
secreted by the tumour cells (a normal pregnancy also produces
hCG and this acts as a smoke screen masking the detection of
tumour relapse); (2) the potential risk of cytotoxic drug induced
damage to the ova (Sieber and Adamson, 1975; Schilsky et al,
1980; Choo et al, 1985); (3) the potentially increased risk of preg-
nancy induced relapse.
The advice to avoid pregnancy for 1 year post-chemotherapy in
women with GTT has been determined by theoretical risks rather
than solid clinical evidence of risk to the mother and foetus.
Consequently, women who do become pregnant during this period
and their physicians are faced with a dilemma of whether to
continue or terminate the pregnancy (Kohorn, 1999). Though there
is increasing published evidence that early pregnancy after GTT
chemotherapy as a whole does not compromise the foetus (Song
et al, 1988; Tuncer et al, 1999a,b; Berkowitz et al, 2000) there is
little data regarding the effect of early pregnancy on subsequent
disease relapse in the patient. Few have assessed these risks sepa-
rately for each treatment group, i.e. those receiving single or
multiple-agent treatment. Here we reviewed the number of relapses
and the maternal and foetal outcomes in 230 women with GTT
who became pregnant within 12 months of completing single or
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number of relapses in women who did not become pregnant
during the ﬁrst 12 months after treatment for GTT and with
national statistics on foetal outcome in unaffected healthy women.
PATIENTS AND METHODS
We retrospectively reviewed the records of 1532 patients who were
given chemotherapy at Charing Cross Hospital for GTT between
December 1969 and January 1998 (Table 1). The patients were
divided into two groups, one receiving ‘single-agent’ and the other
‘multi-agent’ chemotherapy. Patients in the ‘single agent’ group
had low or medium risk disease according to the Charing Cross
modiﬁcation of the WHO GTT scoring system (World Health
Organization Scientiﬁc Group, 1983) used to stage this disease
and received methotrexate and folinic acid (MTX/FA). The
‘multi-agent’ group was composed of those with medium or
high-risk disease requiring treatment with either MTX/FA plus
actinomycin D or combination drug chemotherapy most frequently
consisting of etoposide, methotrexate and actinomycin D (EMA)
alternating weekly with cyclophosphamide and vincristine (CO)
(Bower and Newlands, 1997). Chemotherapy was completed once
hCG levels had fallen to within the normal range and remained
there for at least 6 weeks. Patients initially given ‘single-agent’
treatment but whose hCG levels remained elevated (usually because
of methotrexate-resistance) then received multi-agent chemother-
apy and were included in the ‘multi-agent’ group (Omura, 2000)
in this study. Patients who died within weeks of diagnosis or while
still receiving treatment were excluded from the study.
The outcome of patients who had become pregnant within 12
months of completing chemotherapy was then reviewed. Their
relapse rate was compared to the relapse rate of patients that
had not become pregnant within 12 months. Pregnancy and foetal
outcomes in both groups were also compared.
Statistical considerations
Statistical analysis of the results was performed using the Fisher’s
exact test. The values were considered signiﬁcant at P40.05.
RESULTS
Of the 1532 patients who were treated for GTT, one patient from
the single agent and 71 from the multi-agent chemotherapy groups
died either before or during initial treatment and were excluded
from further analysis. Of the 1009 patients allocated to single agent
(low risk) treatment, 328 then changed to multi-agent chemother-
apy because of methotrexate-resistance. Consequently, 681 patients
received single-agent chemotherapy and 779 patients received
multi-agent treatment. The median ages of the two groups were
well matched (Table 1).
Overall, 78 (5.3%) patients relapsed. Of these, 34 were from the
single-agent and 44 from the multi-agent group (Table 2). Most
relapses occurred within the ﬁrst 12 months (65% in the single-
agent and 82% in the multi-agent treatment groups).
Despite advice to avoid pregnancy in the ﬁrst year of follow-up
230 patients (16% of the total) became pregnant within 12 months
of completing chemotherapy. Of these, the signiﬁcant majority
were from the single-agent group (67%). Of the 230 patients
who became pregnant, three patients within the single agent and
two within the multi-agent group relapsed. Therefore, relapses
did not occur more frequently in either treatment group. More-
over, the relapse rate appeared to be slightly less in the patients
who conceived early than in those women who did not become
pregnant in the ﬁrst 12 months (Table 2).
Interestingly, the pattern of pregnancies differed between the
two treatment groups. Though in both treatment groups, more
pregnancies occurred in the later 6 months of the follow-up period,
this was especially signiﬁcant in the multi-agent group with 25 out
of 77 patients conceiving before 6 months and 52 out of 77 after 6
months (P=0.008) (Figure 1).
The majority (71%) of the 230 pregnancies within the 12 month
follow-up period resulted in full term live births (Table 2). The
time period between completing chemotherapy and conception
did not signiﬁcantly alter eventual pregnancy outcome (Figure 2).
The remaining pregnancies resulted in spontaneous abortions
(11%), voluntary terminations (15%), still births (1%) and new
hydatidiform moles (1.5%) (Table 2). On comparing both groups
there was a signiﬁcantly higher incidence of terminations and
miscarriages in the multi-agent group (Table 2). Of the live births,
one baby died after 4 days with no cause of death established.
Three babies were born with congenital abnormalities (Hirsch-
prung’s disease, ﬁbrosing alveolitis and Down’s syndrome). In
the ﬁve patients who became pregnant and subsequently relapsed,
the preceding treatment had been for complete moles. Four of
the ﬁve women delivered at term but one became breathless at
36 weeks (Table 3, patient 1), was found to have multiple pulmon-
ary metastases and was delivered by Caesarian section. In this case
one pulmonary metastasis was resected and histology conﬁrmed
choriocarcinoma. Genetic analysis was carried out using ﬂuorescent
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Table 1 Patient characteristics
Single agent Multiple agent
Total chemotherapy chemotherapy
Total number of patients 1532 682 850
Early patient deaths 72 1 71
Total minus deaths 1460 681 779
Patient age range 13.8–58 13.8–56.6 15.5–58
(median) (28.2) (27.4) (28.9)
Table 2 Pregnancy and relapse characteristics
Total (%) Single-agent (%) Multi-agent (%) P value
Total number of patients 1460 681 (47) 779 (53) 0.02*
Total number of relapses 78 (5.3) 34 (5) 44 (5.6) 0.64
Relapses within 12 months (as percentage of total relapses) 58 (74) 22 (65) 36 (82) 0.12
Early pregnancies (conceived within 12 months) 230 (16) 153 (22) 77 (10) 50.001*
Relapses following early pregnancy (as percentage of total early pregnancies) 5 (2) 3 (2) 2 (2.6) 1
Early pregnancies reaching full-term (as percentage of total early pregnancies) 164 (71) 120 (78) 44 (57) 0.1
Spontaneous miscarriages 26 (11) 12 (8) 14 (18) 0.04*
Early pregnancies terminated 35 (15) 17 (11) 18 (23) 0.03*
Still births 2 (0.9) 2 (0.9) 0 N/A
New hydatidiform moles 3 (1.3%) 2 (1.3%) 1 (1.2%) 0.7
Congenital abnormalities in babies delivered 3 (1.3%) 1 (0.7%) 2 (2.6%) 0.3
*P-value 40.05 indicates statistical signiﬁcance.
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in order to determine the causative pregnancy. The results shown
in Table 4 demonstrate that the choriocarcinoma arose from the
preceding complete mole. All ﬁve patients were subsequently cured
with combination chemotherapy with an additional hysterectomy
in one case (median follow-up 9 years range 5–30). Moreover,
all their infants thrived (Table 3).
DISCUSSION
This study aimed to investigate the safety of early conception
following chemotherapy for GTT in the single and multi-agent
treatment groups. This was achieved by comparing the pregnancy
outcomes, rates of disease relapse and development of second
tumours to those of other women on our GTT database or in
the general population.
Relapse
Of the 230 patients who conceived in the ﬁrst 12 months of follow-
up only ﬁve relapsed. All of these had had a previous complete
hydatidiform mole. In one patient we conﬁrmed that the subse-
quent choriocarcinoma at relapse originated from the previously
treated molar pregnancy and was not a new post-term choriocarci-
noma. Indeed, in our experience, the preceding hydatidiform mole
is usually the cause of subsequent GTT even in the case of several
intervening pregnancies (unpublished observations). We therefore
believe that the other four cases developed their relapsing GTT
from the previous molar pregnancy.
Our results conﬁrmed that relapse is most likely to occur within
12 months of completing chemotherapy. Patients who have
received more intensive chemotherapy do not seem to be at a high-
er risk of disease recurrence than those on single agent treatment.
In addition, the incidence of relapse is not increased in patients
who become pregnant within 12 months of completing treatment.
Time to conception and termination rate
There were fewer early pregnancies in the women who had received
multi-agent chemotherapy. Of those pregnancies, the majority
occurred beyond 6 months from their treatment completion. This
is likely to be due to anovulation following more intensive treat-
ment. Studies have shown that the ovary has fewer primordial
follicles following chemotherapy (Sieber and Adamson, 1975).
Many patients experience a period of anovulation following the
EMA/CO treatment regimen. The duration of infertility is usually
age-dependent (Kanazawa et al, 2000).
Higher risk patients are also less likely to feel physically well
after multi-agent chemotherapy and prefer to follow GTT guide-
lines and delay conceiving. This is another factor contributing to
the fewer pregnancies in this group and is also reﬂected in their
signiﬁcantly greater number of terminations.
By contrast, the low-risk, methotrexate-containing chemother-
apy group had a less marked difference in distribution of
pregnancies over the 12 months following their chemotherapy. This
is because single agent methotrexate causes fewer menstrual irregu-
larities with most patients maintaining a normal menstrual cycle
throughout their treatment. Generally, these patients have a greater
sense of physical well-being after treatment which contributes to
the higher number of conceptions and fewer terminations. Also
physicians may be more inclined to institute close monitoring
during their pregnancy rather than to advise elective abortion.
Miscarriages
Patients in the multi-agent group had a signiﬁcantly higher
number of spontaneous miscarriages than those receiving single
agent treatment. This again indicates that higher intensity treat-
ment is more likely to have adverse physiological effects. Because
hCG monitoring of patients in this study continued after their
chemotherapy, a pregnancy would be diagnosed earlier. We would
therefore expect higher rates of reported miscarriage than occur in
the general population whose hCG levels are not routinely moni-
tored. Thus we compared our results with those of a study of
217 pregnancies in women whose hCG levels were prospectively
measured with a similar deﬁnition of ‘serological pregnancy’ (Ellish
et al, 1996). This study recorded a miscarriage rate of 13.7% which
compares very favourably with our overall miscarriage rate of 11%.
Other studies have reported early miscarriage rates affecting
between 8% (Whittaker et al, 1983) and 61% (Edmonds et al,
1982) of pregnancies. Consequently, though patients in the
multi-agent group appeared to be at greater risk of miscarriage
(18%) than those in the single agent group (8%), it is unlikely that
they are at greater risk than that of the general population.
Foetal malformation and still birth
Congenital malformations (as deﬁned by the Ofﬁce for National
Statistics (1999)) occurred in 1.3% of the 230 pregnancies
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Figure 1 Histogram showing time to conception patients receiving single
and multi-agent chemotherapy for GTD.
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Figure 2 Histogram showing pregnancy outcomes in women who con-
ceived within 12 months of completing chemotherapy.
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to differ from the 1.6% rate recorded in the general population of
England and Wales between 1971 and 1998 (Ofﬁce for National
Statistics, 1999). Moreover, our results are in accordance with
previous studies showing no correlation between foetal malforma-
tion and previous chemotherapy for GTT (Song et al, 1988; Tuncer
et al, 1999a,b; Berkowitz et al, 2000). Between 1970 and 1997, the
Ofﬁce for National Statistics recorded an average of 7.08 stillbirths
per 1000 pregnancies reported per year in the general population of
England and Wales (0.7%) (Ofﬁce for National Statistics, 1998–
1999). Thus, the 1% still birth rate recorded in this study
compared favourably with these ﬁgures.
Second hydatidiform mole
In this study, three patients (1.3%) developed new hydatidiform
moles, different in histology to their previous invasive GTT and
therefore not deﬁned as relapsed or recurrent disease. The risk of
second molar disease complicating a subsequent pregnancy has
been estimated at around 1% (Vose et al, 1988) and in a recent
retrospective study of 5030 trophoblastic disease patients there
was a recurrent molar pregnancy rate of 0.7% (Lorigan et al,
2000). Thus early pregnancy does not appear to increase the chance
of having a second molar pregnancy.
Conclusion
Early pregnancy following chemotherapy for GTT does not increase
disease relapse. In terms of foetal outcomes, pregnancy following
single agent (low risk) treatment has no effect on rates of miscar-
riage, still birth or congenital malformation. While early pregnancy
after multi-agent treatment does not appear to increase the rate of
still birth or congenital malformation, it may transiently reduce
fertility and relatively increase the chance of miscarriage. Physicians
should still advise patients to avoid pregnancy for 1 year after
chemotherapeutic treatment for GTT. This is because, patients
are at greatest risk of relapse during this time and the rising
hCG of pregnancy can prevent early detection and diagnosis of
disease recurrence. This could place both the patient and foetus
at risk. However, patients who do become pregnant and are despe-
rate to have a child can be assured of a probable favourable
outcome.
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